126 related articles for article (PubMed ID: 38673931)
1. Gastrointestinal safety evaluation of semaglutide for the treatment of type 2 diabetes mellitus: A meta-analysis.
Huang X; Wu M; Lin J; Mou L; Zhang Y; Jiang J
Medicine (Baltimore); 2024 May; 103(21):e38236. PubMed ID: 38787986
[TBL] [Abstract][Full Text] [Related]
2. A systematic review of the effect of semaglutide on lean mass: insights from clinical trials.
Bikou A; Dermiki-Gkana F; Penteris M; Constantinides TK; Kontogiorgis C
Expert Opin Pharmacother; 2024 Apr; 25(5):611-619. PubMed ID: 38629387
[TBL] [Abstract][Full Text] [Related]
3. A comment on 'Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: A systematic review and meta-analysis of randomized controlled trials'.
Goldenberg RM
Diabetes Obes Metab; 2024 Jul; 26(7):2997-2999. PubMed ID: 38576082
[No Abstract] [Full Text] [Related]
4. Discontinuing semaglutide after weight loss: strategy for weight maintenance and a possible new side effect.
Carris NW; Wallace S; DuCoin CG; Mhaskar R; Stern M; Bunnell B
Can J Physiol Pharmacol; 2024 Jun; 102(6):391-395. PubMed ID: 38587178
[TBL] [Abstract][Full Text] [Related]
5. Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population.
Wang W; Volkow ND; Berger NA; Davis PB; Kaelber DC; Xu R
Nat Commun; 2024 May; 15(1):4548. PubMed ID: 38806481
[TBL] [Abstract][Full Text] [Related]
6. Ozempic keeps wowing: trial data show benefits for kidney disease.
Fairbank R
Nature; 2024 Jun; 630(8015):16-17. PubMed ID: 38789608
[No Abstract] [Full Text] [Related]
7. Interaction of Semaglutide and Ziprasidone in a Patient With Schizophrenia: A Case Report.
Hejdak D; Razzak AN; Sun L; Rahman M; Jha P
Cureus; 2024 Apr; 16(4):e59319. PubMed ID: 38817502
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and predictors of traditional medicine use among persons with diabetes in Africa: a systematic review.
Ekpor E; Osei E; Akyirem S
Int Health; 2024 May; 16(3):252-260. PubMed ID: 37706354
[TBL] [Abstract][Full Text] [Related]
9. GLP-1 RA for cardiometabolic risk reduction in obesity - How do we best describe benefit and value?
Kumar S; Blaha MJ
Am J Prev Cardiol; 2024 Jun; 18():100682. PubMed ID: 38840935
[TBL] [Abstract][Full Text] [Related]
10. Peer Review for "Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis".
Anonymous
JMIRx Med; 2024 May; 5():e59120. PubMed ID: 38738851
[No Abstract] [Full Text] [Related]
11. A call to update anesthetic protocols: the hidden risks of semaglutide.
Santos LB; Nersessian RSF; Silveira SQ; Silva LM; Matheus GD; Buniotti BP; Vieira JE; Mizubuti GB
Can J Anaesth; 2024 May; ():. PubMed ID: 38807009
[No Abstract] [Full Text] [Related]
12. Safety of Semaglutide.
Smits MM; Van Raalte DH
Front Endocrinol (Lausanne); 2021; 12():645563. PubMed ID: 34305810
[TBL] [Abstract][Full Text] [Related]
13. Semaglutide once-weekly: improved efficacy with a new safety warning.
Coon SA; Crannage EF; Kerwin LC; Guyton JE
Expert Rev Clin Pharmacol; 2018 Nov; 11(11):1061-1072. PubMed ID: 30296182
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of the glucagon-like peptide-1 receptor agonist oral semaglutide in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
Li J; He K; Ge J; Li C; Jing Z
Diabetes Res Clin Pract; 2021 Feb; 172():108656. PubMed ID: 33434602
[TBL] [Abstract][Full Text] [Related]
15. Oral Semaglutide: First-in-Class Oral GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus.
Cowart K
Ann Pharmacother; 2020 May; 54(5):478-485. PubMed ID: 31744308
[No Abstract] [Full Text] [Related]
16. Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review.
Feier CVI; Vonica RC; Faur AM; Streinu DR; Muntean C
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673931
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials.
Aroda VR; Ahmann A; Cariou B; Chow F; Davies MJ; Jódar E; Mehta R; Woo V; Lingvay I
Diabetes Metab; 2019 Oct; 45(5):409-418. PubMed ID: 30615985
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
